Illumina (NASDAQ:ILMN – Free Report) had its target price upped by Evercore ISI from $235.00 to $240.00 in a report issued on Thursday morning, Marketbeat.com reports. Evercore ISI currently has an outperform rating on the life sciences company’s stock.
Several other equities analysts have also recently weighed in on ILMN. Bank of America decreased their price objective on Illumina from $230.00 to $210.00 in a report on Thursday. Royal Bank of Canada decreased their price objective on Illumina from $337.00 to $328.00 and set an outperform rating for the company in a report on Tuesday, August 8th. Stifel Nicolaus decreased their price objective on Illumina from $265.00 to $225.00 and set a buy rating for the company in a report on Thursday. Credit Suisse Group reduced their price target on Illumina from $225.00 to $200.00 and set a neutral rating for the company in a report on Thursday. Finally, Citigroup reduced their price target on Illumina from $180.00 to $150.00 and set a sell rating for the company in a report on Thursday. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, Illumina has an average rating of Hold and a consensus target price of $235.26.
View Our Latest Stock Analysis on Illumina
Illumina Stock Performance
Illumina (NASDAQ:ILMN – Get Free Report) last released its quarterly earnings results on Wednesday, August 9th. The life sciences company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.30. The firm had revenue of $1.18 billion for the quarter, compared to the consensus estimate of $1.16 billion. Illumina had a positive return on equity of 1.97% and a negative net margin of 93.86%. The company’s revenue for the quarter was up 1.2% on a year-over-year basis. During the same quarter last year, the business posted $0.57 EPS. Equities analysts expect that Illumina will post 0.83 EPS for the current fiscal year.
Insiders Place Their Bets
In other news, SVP Susan H. Tousi sold 500 shares of Illumina stock in a transaction that occurred on Monday, July 24th. The shares were sold at an average price of $190.08, for a total value of $95,040.00. Following the completion of the sale, the senior vice president now directly owns 46,022 shares in the company, valued at $8,747,861.76. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Company insiders own 0.13% of the company’s stock.
Institutional Investors Weigh In On Illumina
Hedge funds and other institutional investors have recently made changes to their positions in the business. Luts & Greenleigh Group Inc. raised its position in Illumina by 0.6% during the first quarter. Luts & Greenleigh Group Inc. now owns 8,220 shares of the life sciences company’s stock valued at $1,912,000 after purchasing an additional 50 shares in the last quarter. Carnegie Capital Asset Management LLC grew its stake in shares of Illumina by 4.5% during the first quarter. Carnegie Capital Asset Management LLC now owns 1,171 shares of the life sciences company’s stock worth $272,000 after buying an additional 50 shares during the last quarter. Eukles Asset Management grew its stake in shares of Illumina by 0.9% during the first quarter. Eukles Asset Management now owns 5,747 shares of the life sciences company’s stock worth $1,336,000 after buying an additional 51 shares during the last quarter. Raymond James Trust N.A. grew its stake in shares of Illumina by 2.8% during the fourth quarter. Raymond James Trust N.A. now owns 1,883 shares of the life sciences company’s stock worth $381,000 after buying an additional 52 shares during the last quarter. Finally, Kentucky Retirement Systems grew its stake in shares of Illumina by 0.4% in the fourth quarter. Kentucky Retirement Systems now owns 12,351 shares of the life sciences company’s stock worth $2,497,000 after purchasing an additional 54 shares during the last quarter. 88.66% of the stock is currently owned by institutional investors and hedge funds.
About Illumina
Illumina, Inc develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; and whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Further Reading
- Five stocks we like better than Illumina
- Are Penny Stocks a Good Fit for Your Portfolio?
- MarketBeat Week in Review – 8/7 – 8/11
- How to Invest in Artificial Intelligence
- 3 Retailers To Watch Closely Next Week
- How to Invest in Apparel Stocks
- Investing in Coffee: 3 Great Strategies to Consider
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.
